We commend Krakowski I, et al. [1], for their recent article describing a recent prospective study that analyzes the treatment response, prognosis, and prognostic factors in metastatic melanoma patients receiving immune checkpoint inhibitors (ICIs) and MAPKinase inhibitors (MAPKis).
No takes yet. Share an insight, caveat, or question.
Joanna Łudzik (2022) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: